Duodenal mucosal resurfacing (DMR), an investigational endoscopic procedure, has shown promise in helping patients maintain weight loss after discontinuing GLP-1 receptor agonist medications such as Ozempic and Wegovy, according to findings presented at Digestive Disease Week® (DDW) 2026. The minimally invasive technique, which uses hydrothermal ablation to renew the lining of the upper small intestine, was evaluated in a randomized, double-blind, sham-controlled trial known as REMAIN-1. Results indicated that participants who underwent DMR preserved significantly more of their weight loss compared to those who received a placebo procedure, offering a potential “off-ramp” for individuals seeking to discontinue long-term medication use due to cost, side effects, or personal preference.
The REMAIN-1 trial enrolled adults aged 21 to 70 without diabetes who had a body mass index between 30 and 45 kg/m² and were naive to GLP-1 therapy. After achieving at least 15% total body weight loss during a tirzepatide run-in phase, participants stopped the medication and were randomized in a 2:1 ratio to either receive DMR or a sham procedure. All patients received structured lifestyle counseling throughout the study. At the six-month follow-up, those who underwent the actual DMR procedure regained an average of only about 7 pounds, preserving more than 80% of their initial weight loss. In contrast, the control group regained roughly twice as much weight, with participants in the sham group experiencing substantially greater weight rebound.
“Nearly one in five adults report having taken a GLP-1 receptor agonist drug at some point, and the results can be dramatic,” said lead author Shelby Sullivan, MD, during a press briefing ahead of DDW 2026. “However, an estimated 60-70% of patients discontinue these drugs within the first year for a variety of reasons, including cost, side effects, or simply not wanting to stay on a medication long-term.” Sullivan emphasized that DMR aims to address the metabolic dysregulation that often underlies weight regain after stopping GLP-1 therapies by stimulating the regrowth of healthier duodenal tissue, which may trigger a lasting metabolic reset.
The procedure itself is performed on an outpatient basis and typically takes less than an hour. During DMR, a catheter-mounted balloon delivers controlled thermal energy to the duodenal mucosa, selectively ablating the damaged lining. This process is intended to promote the regeneration of a healthier epithelial layer, which researchers believe plays a key role in nutrient sensing and metabolic signaling. Participants in the trial reported minimal discomfort during and after the procedure, with many unable to distinguish whether they had received the active treatment or the sham, supporting the validity of the blinded design.
These findings build upon earlier research suggesting that the duodenum plays a significant role in metabolic homeostasis, particularly in individuals with obesity. By targeting this specific segment of the gastrointestinal tract, DMR seeks to modify the gut’s interaction with nutrients and hormones in a way that sustains the benefits achieved during pharmacological weight loss. Unlike bariatric surgery, which alters anatomy permanently, DMR is designed to be reversible and repeatable if needed, offering a less invasive alternative for metabolic intervention.
Experts caution that while the midpoint results of REMAIN-1 are encouraging, the trial is ongoing and final data will be necessary to confirm the durability of the effect beyond six months. Long-term safety, optimal patient selection, and the potential need for repeat procedures remain areas for future investigation. Nevertheless, the ability to maintain weight loss without ongoing pharmacotherapy could represent a meaningful advancement in obesity care, particularly for populations facing barriers to chronic medication access.
As of April 2026, the REMAIN-1 trial continues to enroll participants at multiple centers across the United States. Updates on the study’s progress are expected to be shared at upcoming medical conferences, including future iterations of Digestive Disease Week. For individuals interested in learning more about eligibility or trial locations, official information is available through the study’s sponsoring institution and clinical trial registries.
The investigation into endoscopic therapies like DMR reflects a broader shift toward gut-centered approaches in managing metabolic disease. As research advances, such interventions may offer complementary or alternative strategies to traditional pharmacological and surgical options, expanding the toolkit available to clinicians and patients alike.
If you found this information helpful, consider sharing it with others who may benefit. Join the conversation by leaving a comment below with your thoughts or questions about emerging treatments for weight maintenance after GLP-1 therapy.